← Back to catalogue
exofin Fusion Skin Closure System 22cm
EUDAMEDFDA 510(k)Class IIa (EU MDR)
Ref EF70460CEModel EF70422CERef EF70430CE
Identity
- Device Name
- exofin Fusion Skin Closure System 22cm EUDAMED
- Model / Reference
- EF70422CE EUDAMEDEF70460CE EUDAMEDEF70430CE EUDAMED
Identifiers
- Primary DI / UDI-DI
- 00854137001566 EUDAMED00854137001412 EUDAMED
- Basic UDI-DI
- 854137001OMDJZ EUDAMED
- Direct Marketing DI
- 00854137001566 EUDAMED00854137001412 EUDAMED
- EMDN Code
- H900199 TISSUE ADHESIVES - OTHER EUDAMED
Classification
- Device Class
- Class IIa EUDAMED
- Market of Registration
- Poland EUDAMED
Clinical & Handling
Sterile
Yes
EUDAMED
Implantable
No
EUDAMED
Reusable
No
EUDAMED
Contains Latex
No
EUDAMED
Reprocessed
No
EUDAMED
CMR Substance
No
EUDAMED
Human-derived
No
EUDAMED
Human Tissues
No
EUDAMED
Animal Tissues
No
EUDAMED
Endocrine Disruptor
No
EUDAMED
Administering Medicine
No
EUDAMED
Measuring Function
No
EUDAMED
Incorporates Medicinal Product
No
EUDAMED
exofin Fusion Skin Closure System 22cm by Chemence Medical Inc. — Class IIa — FDA_510K, MDR — listed in EUDAMED, FDA 510(k) — regulatory data on deviCERTS
Authorization Coverage (2 countries)
Regulatory Authorizations
United States Active
FDA_510K
United States Active
FDA_510K
European Union Active
CE/MDR
| Source | Region | Type | Cert / Approval No. | Class | Status |
|---|---|---|---|---|---|
| FDA 510(k) | United States | FDA_510K | K191461 | Class IIa | Active |
| FDA 510(k) | United States | FDA_510K | K171442 | Class IIa | Active |
| EUDAMED | European Union | CE/MDR | 854137001OMDJZ | Class IIa | Active |
Is this your device? Claim it to add documentation and request validation.
Manufacturer
- Manufacturer
- Chemence Medical Inc.
- EUDAMED SRN
- US-MF-000000888
- Authorised Representative
- Atlantico Systems, Ltd. IE-AR-000000208
Sources (3)
- EUDAMED e62f7ab5-945c-4194-ab8b-f6c01fb0da43 61 fields · synced Sep 18, 2026
- EUDAMED 431c5811-f910-4ddd-9ee6-5344bd84d6c2 61 fields · synced May 18, 2026
- FDA 510(k) K191461 1 fields · synced May 18, 2026